Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients

D. Zugna, R. Senetta, S. Osella-Abate, M. T. Fierro, A. Pisacane, A. Zaccagna, A. Sapino, V. Bataille, A. Maurichi, F. Picciotto, P. Cassoni, P. Quaglino, S. Ribero

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background:Sentinel lymph node (SLN)-positive melanoma patients are a heterogeneous group of patients with survival rates ranging from 20 to over 80%. No data are reported concerning the role of histological regression on survival in stage III melanoma.Methods:The study included 365 patients with positive SLN from two distinct hospitals. The model was developed on patients from 'AOU Città della Salute e della Scienza di Torino', and externally validated on patients from IRCCS of Candiolo. Survival analyses were carried out according to the presence of regression and adjusted for all other prognostic factors.Results:Among patients followed at 'AOU Città della Salute e della Scienza di Torino' (n=264), the median follow-up time to death or censoring (whatever two events occurred earlier) was 2.7 years since diagnosis (interquartile range: 1.3-5.8). In all, 79 patients died from melanoma and 11 from other causes. Histological regression (n=43) was associated with a better prognosis (sub-HR=0.34, CI 0.12-0.92), whereas the other factors above showed an inverse association. In the external validation, the concordance index was 0.97 at 1 year and decreased to 0.66 at 3 years and to 0.59 at 5 years. Adding histological regression in the prognostic model increased the discriminative ability to 0.75 at 3 years and to 0.62 at 5 years. Finally, using a cutoff of 20% for the risk of death led to a net re-classification improvement of 15 and 11% at 3 and 5 years after diagnosis, respectively.Conclusions:Histological regression could lead to an improvement in prognostic prediction in patients with stage III-positive SLN melanoma.

Original languageEnglish
Pages (from-to)398-404
Number of pages7
JournalBritish Journal of Cancer
Volume118
Issue number3
DOIs
Publication statusPublished - Feb 6 2018

Fingerprint

Melanoma
Sentinel Lymph Node
Survival Analysis
Survival Rate
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. / Zugna, D.; Senetta, R.; Osella-Abate, S.; Fierro, M. T.; Pisacane, A.; Zaccagna, A.; Sapino, A.; Bataille, V.; Maurichi, A.; Picciotto, F.; Cassoni, P.; Quaglino, P.; Ribero, S.

In: British Journal of Cancer, Vol. 118, No. 3, 06.02.2018, p. 398-404.

Research output: Contribution to journalArticle

Zugna, D, Senetta, R, Osella-Abate, S, Fierro, MT, Pisacane, A, Zaccagna, A, Sapino, A, Bataille, V, Maurichi, A, Picciotto, F, Cassoni, P, Quaglino, P & Ribero, S 2018, 'Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients', British Journal of Cancer, vol. 118, no. 3, pp. 398-404. https://doi.org/10.1038/bjc.2017.397
Zugna, D. ; Senetta, R. ; Osella-Abate, S. ; Fierro, M. T. ; Pisacane, A. ; Zaccagna, A. ; Sapino, A. ; Bataille, V. ; Maurichi, A. ; Picciotto, F. ; Cassoni, P. ; Quaglino, P. ; Ribero, S. / Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. In: British Journal of Cancer. 2018 ; Vol. 118, No. 3. pp. 398-404.
@article{5d7b184ba41341b595bf31fa2a643a5f,
title = "Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients",
abstract = "Background:Sentinel lymph node (SLN)-positive melanoma patients are a heterogeneous group of patients with survival rates ranging from 20 to over 80{\%}. No data are reported concerning the role of histological regression on survival in stage III melanoma.Methods:The study included 365 patients with positive SLN from two distinct hospitals. The model was developed on patients from 'AOU Citt{\`a} della Salute e della Scienza di Torino', and externally validated on patients from IRCCS of Candiolo. Survival analyses were carried out according to the presence of regression and adjusted for all other prognostic factors.Results:Among patients followed at 'AOU Citt{\`a} della Salute e della Scienza di Torino' (n=264), the median follow-up time to death or censoring (whatever two events occurred earlier) was 2.7 years since diagnosis (interquartile range: 1.3-5.8). In all, 79 patients died from melanoma and 11 from other causes. Histological regression (n=43) was associated with a better prognosis (sub-HR=0.34, CI 0.12-0.92), whereas the other factors above showed an inverse association. In the external validation, the concordance index was 0.97 at 1 year and decreased to 0.66 at 3 years and to 0.59 at 5 years. Adding histological regression in the prognostic model increased the discriminative ability to 0.75 at 3 years and to 0.62 at 5 years. Finally, using a cutoff of 20{\%} for the risk of death led to a net re-classification improvement of 15 and 11{\%} at 3 and 5 years after diagnosis, respectively.Conclusions:Histological regression could lead to an improvement in prognostic prediction in patients with stage III-positive SLN melanoma.",
author = "D. Zugna and R. Senetta and S. Osella-Abate and Fierro, {M. T.} and A. Pisacane and A. Zaccagna and A. Sapino and V. Bataille and A. Maurichi and F. Picciotto and P. Cassoni and P. Quaglino and S. Ribero",
year = "2018",
month = "2",
day = "6",
doi = "10.1038/bjc.2017.397",
language = "English",
volume = "118",
pages = "398--404",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients

AU - Zugna, D.

AU - Senetta, R.

AU - Osella-Abate, S.

AU - Fierro, M. T.

AU - Pisacane, A.

AU - Zaccagna, A.

AU - Sapino, A.

AU - Bataille, V.

AU - Maurichi, A.

AU - Picciotto, F.

AU - Cassoni, P.

AU - Quaglino, P.

AU - Ribero, S.

PY - 2018/2/6

Y1 - 2018/2/6

N2 - Background:Sentinel lymph node (SLN)-positive melanoma patients are a heterogeneous group of patients with survival rates ranging from 20 to over 80%. No data are reported concerning the role of histological regression on survival in stage III melanoma.Methods:The study included 365 patients with positive SLN from two distinct hospitals. The model was developed on patients from 'AOU Città della Salute e della Scienza di Torino', and externally validated on patients from IRCCS of Candiolo. Survival analyses were carried out according to the presence of regression and adjusted for all other prognostic factors.Results:Among patients followed at 'AOU Città della Salute e della Scienza di Torino' (n=264), the median follow-up time to death or censoring (whatever two events occurred earlier) was 2.7 years since diagnosis (interquartile range: 1.3-5.8). In all, 79 patients died from melanoma and 11 from other causes. Histological regression (n=43) was associated with a better prognosis (sub-HR=0.34, CI 0.12-0.92), whereas the other factors above showed an inverse association. In the external validation, the concordance index was 0.97 at 1 year and decreased to 0.66 at 3 years and to 0.59 at 5 years. Adding histological regression in the prognostic model increased the discriminative ability to 0.75 at 3 years and to 0.62 at 5 years. Finally, using a cutoff of 20% for the risk of death led to a net re-classification improvement of 15 and 11% at 3 and 5 years after diagnosis, respectively.Conclusions:Histological regression could lead to an improvement in prognostic prediction in patients with stage III-positive SLN melanoma.

AB - Background:Sentinel lymph node (SLN)-positive melanoma patients are a heterogeneous group of patients with survival rates ranging from 20 to over 80%. No data are reported concerning the role of histological regression on survival in stage III melanoma.Methods:The study included 365 patients with positive SLN from two distinct hospitals. The model was developed on patients from 'AOU Città della Salute e della Scienza di Torino', and externally validated on patients from IRCCS of Candiolo. Survival analyses were carried out according to the presence of regression and adjusted for all other prognostic factors.Results:Among patients followed at 'AOU Città della Salute e della Scienza di Torino' (n=264), the median follow-up time to death or censoring (whatever two events occurred earlier) was 2.7 years since diagnosis (interquartile range: 1.3-5.8). In all, 79 patients died from melanoma and 11 from other causes. Histological regression (n=43) was associated with a better prognosis (sub-HR=0.34, CI 0.12-0.92), whereas the other factors above showed an inverse association. In the external validation, the concordance index was 0.97 at 1 year and decreased to 0.66 at 3 years and to 0.59 at 5 years. Adding histological regression in the prognostic model increased the discriminative ability to 0.75 at 3 years and to 0.62 at 5 years. Finally, using a cutoff of 20% for the risk of death led to a net re-classification improvement of 15 and 11% at 3 and 5 years after diagnosis, respectively.Conclusions:Histological regression could lead to an improvement in prognostic prediction in patients with stage III-positive SLN melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85041694430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041694430&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.397

DO - 10.1038/bjc.2017.397

M3 - Article

AN - SCOPUS:85041694430

VL - 118

SP - 398

EP - 404

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -